Which patients with ER positive/HER2 negative breast cancer will benefit from chemotherapy? EndoPredict provides 10 years’ personalized chemobenefit for every patient to guide decision-making.
Prediction of chemotherapy benefit by EndoPredict was shown in a large cross-cohort study with over 3,700 pre- and postmenopausal patients with ER positive/HER2 negative, node positive and node negative breast cancer.
Fill out the form below to download your free copy of the clinical summary to learn more about this key study.